{"title":"Popular gut probiotic completely craps out in randomized controlled trial","link":"https://arstechnica.com/health/2024/10/popular-gut-probiotic-completely-craps-out-in-randomized-controlled-trial/","date":1727976849000,"content":"<p>Any striking marketing claims in companies' ads about the gut benefits of a popular probiotic may be full of, well, the same thing that has their target audience backed up.</p>\n<p>In a randomized controlled trial, the probiotic <em>Bifidobacterium animalis</em> subsp. <em>lactis</em>—used in many probiotic products, including Dannon's Activia yogurts—did nothing to improve bowel health in people with constipation, according to <a href=\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824333\">data from a randomized triple-blind placebo-controlled clinical trial</a> published Wednesday in JAMA Network Open.</p>\n<p>The study adds to a mixed and mostly unconvincing body of scientific literature on the bowel benefits of the bacterium, substrains of which are sometimes sold with faux scientific-sounding names in products. Dannon, for instance, previously marketed its substrain, DN-173 010, as \"Bifidus regularis.\"</p><p><a href=\"https://arstechnica.com/health/2024/10/popular-gut-probiotic-completely-craps-out-in-randomized-controlled-trial/\">Read full article</a></p>\n<p><a href=\"https://arstechnica.com/health/2024/10/popular-gut-probiotic-completely-craps-out-in-randomized-controlled-trial/#comments\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"788e94336f1be510df33850cf9b3366a05332f62961d0fff0a73d404bb459e59","category":"Tech"}